retatrutide clinical trials canada Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide 2026: 28.3% Weight Loss
Description
Severance EG, Gressitt KL, Yang S, Stallings CR, Origoni AE, Vaughan C, et al
.webp)
Moreover, a thorough understanding of the specific benefits and limitations of each GLP-1 RA is essential for informed clinical decision-making

However, this efficacy came alongside a notable burden of gastrointestinal side effects, particularly at higher doses

Dutka M, Bobiski R, Francuz T, et al

Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine

If weight loss is a treatment goal , GLP-1 medications are a more appropriate choice
